a Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB) , Aruna Asaf Ali Marg, New Delhi 110067 , India.
J Biomol Struct Dyn. 2019 Mar;37(4):931-943. doi: 10.1080/07391102.2018.1444509. Epub 2018 Mar 5.
5-HydroxyTriptamine 2A antagonists are potential targets for treatment of various cerebrovascular and cardiovascular disorders. In this study, we have developed and performed a unique screening pipeline for filtering ZINC database compounds on the basis of similarities to known antagonists to determine novel small molecule antagonists of 5-HydroxyTriptamine 2A. The screening pipeline is based on 2D similarity, 3D dissimilarity and a combination of 2D/3D similarity. The shortlisted compounds were docked to a 5-HydroxyTriptamine 2A homology-based model, and complexes with low binding energies (287 complexes) were selected for molecular dynamics (MD) simulations in a lipid bilayer. The MD simulations of the shortlisted compounds in complex with 5-HydroxyTriptamine 2A confirmed the stability of the complexes and revealed novel interaction insights. The receptor residues S239, N343, S242, S159, Y370 and D155 predominantly participate in hydrogen bonding. π-π stacking is observed in F339, F340, F234, W151 and W336, whereas hydrophobic interactions are observed amongst V156, F339, F234, V362, V366, F340, V235, I152 and W151. The known and potential antagonists shortlisted by us have similar overlapping molecular interaction patterns. The 287 potential 5-HydroxyTriptamine 2A antagonists may be experimentally verified.
5-羟色胺 2A 拮抗剂是治疗各种脑血管和心血管疾病的潜在靶点。在这项研究中,我们开发并执行了一个独特的筛选管道,基于与已知拮抗剂的相似性对 ZINC 数据库化合物进行筛选,以确定 5-羟色胺 2A 的新型小分子拮抗剂。筛选管道基于 2D 相似性、3D 不相似性和 2D/3D 相似性的组合。被提名的化合物与 5-羟色胺 2A 同源模型对接,选择具有低结合能的复合物(287 个复合物)进行脂质双层中的分子动力学(MD)模拟。被提名的化合物与 5-羟色胺 2A 形成复合物的 MD 模拟证实了复合物的稳定性,并揭示了新的相互作用见解。受体残基 S239、N343、S242、S159、Y370 和 D155 主要参与氢键。观察到 F339、F340、F234、W151 和 W336 之间的π-π堆积,而观察到 V156、F339、F234、V362、V366、F340、V235、I152 和 W151 之间的疏水相互作用。我们提名的已知和潜在拮抗剂具有相似的重叠分子相互作用模式。这 287 种潜在的 5-羟色胺 2A 拮抗剂可能需要经过实验验证。